Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Chimeric antigen receptor (CAR) T-cell therapy is an effective new treatment for hematologic malignancies. Two CAR T-cell products are now approved for clinical use by the U.S. FDA: tisagenlecleucel for pediatric acute lymphoblastic leukemia (ALL) and adult diffuse large B-cell lymphoma subtypes (DLBCL), and axicabtagene ciloleucel for DLBCL. CAR T-cell therapies are being developed for multiple myeloma, and clear evidence of clinical activity has been generated. A barrier to widespread use of CAR T-cell therapy is toxicity, primarily cytokine release syndrome (CRS) and neurologic toxicity.
Source: Blood Reviews - Category: Hematology Authors: Jennifer N. Brudno, James N. Kochenderfer Tags: Review Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Brain | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Neurology | Pediatrics | Toxicology